



2026/3

15.1.2026

DECISION OF THE EEA JOINT COMMITTEE No 196/2025
of 19 September 2025
amending Annex II (Technical regulations, standards, testing and certification) to the
EEA Agreement [2026/3]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,

Whereas:

- (1) Commission Implementing Regulation (EU) 2025/808 of 5 May 2025 amending Implementing Regulation (EU) 2015/408 as regards the deletion of gamma-cyhalothrin, ipconazole and oxamyl from the list of active substances to be considered as candidates for substitution ⁽¹⁾ is to be incorporated into the EEA Agreement.
- (2) Commission Implementing Regulation (EU) 2025/833 of 5 May 2025 renewing the approval of the active substance lenacil in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulations (EU) No 540/2011 and (EU) 2015/408 ⁽²⁾ is to be incorporated into the EEA Agreement.
- (3) Commission Implementing Regulation (EU) 2025/845 of 5 May 2025 approving the active substance elemental iron as a low-risk active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011 ⁽³⁾ is to be incorporated into the EEA Agreement.
- (4) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

Chapter XV of Annex II to the EEA Agreement is amended as follows:

1. The following indents are added in point 13a (Commission Implementing Regulation (EU) No 540/2011):
 - ‘— **32025 R 0833**: Commission Implementing Regulation (EU) 2025/833 of 5 May 2025 (OJ L, 2025/833, 6.5.2025),
 - **32025 R 0845**: Commission Implementing Regulation (EU) 2025/845 of 5 May 2025 (OJ L, 2025/845, 6.5.2025).’
2. The following indents are added in point 13zzzzt (Commission Implementing Regulation (EU) 2015/408):
 - ‘— **32025 R 0808**: Commission Implementing Regulation (EU) 2025/808 of 5 May 2025 (OJ L, 2025/808, 6.5.2025),
 - **32025 R 0833**: Commission Implementing Regulation (EU) 2025/833 of 5 May 2025 (OJ L, 2025/833, 6.5.2025).’

⁽¹⁾ OJ L, 2025/808, 6.5.2025, ELI: http://data.europa.eu/eli/reg_impl/2025/808/oj.

⁽²⁾ OJ L, 2025/833, 6.5.2025, ELI: http://data.europa.eu/eli/reg_impl/2025/833/oj.

⁽³⁾ OJ L, 2025/845, 6.5.2025, ELI: http://data.europa.eu/eli/reg_impl/2025/845/oj.

3. The following points are inserted after point 13zzzzzzzzzzzzzh (Commission Implementing Regulation (EU) 2025/150):
- '13zzzzzzzzzzzzzi. **32025 R 0833**: Commission Implementing Regulation (EU) 2025/833 of 5 May 2025 renewing the approval of the active substance lenacil in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulations (EU) No 540/2011 and (EU) 2015/408 (OJ L, 2025/833, 6.5.2025).
- 13zzzzzzzzzzzzzj. **32025 R 0845**: Commission Implementing Regulation (EU) 2025/845 of 5 May 2025 approving the active substance elemental iron as a low-risk active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011 (OJ L, 2025/845, 6.5.2025).'

Article 2

The texts of Implementing Regulations (EU) 2025/808, (EU) 2025/833 and (EU) 2025/845 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

Article 3

This Decision shall enter into force on 20 September 2025, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*).

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

Done at Brussels, 19 September 2025.

For the EEA Joint Committee
The President
Stefán Haukur JÓHANNESON

(*) No constitutional requirements indicated.